Millennium Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Millennium Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-79	Closed	-$55.8K	–	6668
2023 Q3	$55.8K	Sell	79 -43	-35%	-$184K	﹤0.01%	5455
2023 Q2	$558K	Sell	122 -41	-25%	-$142K	﹤0.01%	4462
2023 Q1	$432K	Sell	163 -32	-16%	-$93.7K	﹤0.01%	4691
2022 Q4	$508K	Sell	195 -44	-18%	-$153K	﹤0.01%	4734
2022 Q3	$947K	Sell	239 -174	-42%	-$684K	﹤0.01%	4387
2022 Q2	$1.08M	Buy	413 +357	+638%	+$930K	﹤0.01%	4296
2022 Q1	$181K	Sell	56 -141	-72%	-$607K	﹤0.01%	5866
2021 Q4	$1.24M	Sell	197 -155	-44%	-$1.19M	﹤0.01%	4208
2021 Q3	$3.25M	Sell	352 -137	-28%	-$1.18M	﹤0.01%	3362
2021 Q2	$4.96M	Buy	489 +321	+191%	+$5.27M	﹤0.01%	2765
2021 Q1	$3.22M	Buy	+168	New	+$1.96M	﹤0.01%	3064
2019 Q2	–	Sell	-16	Closed	-$213K	–	4559
2019 Q1	$213K	Buy	+16	New	+$259K	﹤0.01%	3706
2015 Q2	–	Hold	0	–	-$54K	–	3948
2015 Q1	–	Hold	0	–	–	–	3465
2014 Q2	–	Hold	0	–	-$24K	–	3985
2014 Q1	–	Hold	0	–	–	–	3382

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's SEEL Position: Q4 2023 in Review

Millennium Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 79 shares — an estimated $55.8K sold.

Millennium Management first reported a position in SEEL in Q1 2019 and held it in 12 quarters. The position peaked at $4.96M in Q2 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Millennium Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Millennium Management sold 79 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $55.8K.
Millennium Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 12 quarters.
Millennium Management's Seelos Therapeutics, Inc. Common Stock position peaked at $4.96M in Q2 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.